TENAX THERAPEUTICS INC (TENX) Stock Price, Quote, News and Overview
NASDAQ:TENX - Nasdaq - US88032L6056 - Common Stock - Currency: USD
TENX Quote, Performance and Key Statistics
5.46
+0.36 (+7.06%)
The current stock price of TENX is 5.46 USD. In the past month the price decreased by -12.78%. In the past year, price increased by 56.9%.
TENX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.5 | 313.20B | ||
| AMGN | AMGEN INC | 14.02 | 149.41B | ||
| GILD | GILEAD SCIENCES INC | 23.08 | 132.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1698 | 126.59B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.88 | 64.26B | ||
| ARGX | ARGENX SE - ADR | 319.7 | 36.31B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.48B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.60B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.85B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 24.51B | ||
| NTRA | NATERA INC | N/A | 20.08B | ||
| BIIB | BIOGEN INC | 7.17 | 17.30B |
Related stock screener links
About TENX
Company Profile
Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company is headquartered in Chapel Hill, North Carolina and currently employs 5 full-time employees. The firm is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The firm's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The firm is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The firm has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Company Info
TENAX THERAPEUTICS INC
101 Glen Lennox Drive, Suite 300
Chapel Hill NORTH CAROLINA 27560 US
CEO: Anthony DiTonno
Employees: 6
Company Website: http://www.tenaxthera.com/
Investor Relations: http://investors.tenaxthera.com/
Phone: 19198552100
TENAX THERAPEUTICS INC / TENX FAQ
What is the stock price of TENAX THERAPEUTICS INC today?
The current stock price of TENX is 5.46 USD. The price increased by 7.06% in the last trading session.
What is the ticker symbol for TENAX THERAPEUTICS INC stock?
The exchange symbol of TENAX THERAPEUTICS INC is TENX and it is listed on the Nasdaq exchange.
On which exchange is TENX stock listed?
TENX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TENAX THERAPEUTICS INC stock?
10 analysts have analysed TENX and the average price target is 22.44 USD. This implies a price increase of 310.99% is expected in the next year compared to the current price of 5.46. Check the TENAX THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TENAX THERAPEUTICS INC worth?
TENAX THERAPEUTICS INC (TENX) has a market capitalization of 21.68M USD. This makes TENX a Nano Cap stock.
How many employees does TENAX THERAPEUTICS INC have?
TENAX THERAPEUTICS INC (TENX) currently has 6 employees.
What are the support and resistance levels for TENAX THERAPEUTICS INC (TENX) stock?
TENAX THERAPEUTICS INC (TENX) has a support level at 5.38 and a resistance level at 5.94. Check the full technical report for a detailed analysis of TENX support and resistance levels.
Should I buy TENAX THERAPEUTICS INC (TENX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TENX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TENX, evaluating the profitability, health, valuation and growth aspects
- TENAX THERAPEUTICS INC (TENX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TENAX THERAPEUTICS INC (TENX) Sales and EPS estimates to see what analysts future expectations are.
- TENAX THERAPEUTICS INC (TENX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TENAX THERAPEUTICS INC (TENX) Insider and Institutional Ownership to learn about the owners and their transactions.
- TENAX THERAPEUTICS INC (TENX) Stock Chart to make your own analysis
- TENAX THERAPEUTICS INC (TENX) Latest news and press-releases to stay up to date.
Does TENAX THERAPEUTICS INC (TENX) stock pay dividends?
TENX does not pay a dividend.
When does TENAX THERAPEUTICS INC (TENX) report earnings?
TENAX THERAPEUTICS INC (TENX) will report earnings on 2025-05-12.
What is the Price/Earnings (PE) ratio of TENAX THERAPEUTICS INC (TENX)?
TENAX THERAPEUTICS INC (TENX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.32).
What is the Short Interest ratio of TENAX THERAPEUTICS INC (TENX) stock?
The outstanding short interest for TENAX THERAPEUTICS INC (TENX) is 11.23% of its float. Check the ownership tab for more information on the TENX short interest.
TENX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to TENX. When comparing the yearly performance of all stocks, TENX is one of the better performing stocks in the market, outperforming 91.83% of all stocks.
TENX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TENX. TENX has a great financial health rating, but its profitability evaluates not so good.
TENX Financial Highlights
Over the last trailing twelve months TENX reported a non-GAAP Earnings per Share(EPS) of -5.32. The EPS increased by 84.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.21% | ||
| ROE | -19.13% | ||
| Debt/Equity | 0 |
TENX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 88% to TENX. The Buy consensus is the average rating of analysts ratings from 10 analysts.